Nurbanu SEZAK, Can Hüseyin HEKİMOĞLU, Nesrin TÜRKER, Sibel EL, Serap URAL, İlknur VARDAR, Bahar ÖRMEN, Figen KAPTAN

Prevalence and associated factors of thrombocytopenia among human immunodeficiency virus-infected patients at a tertiary care hospital in İzmir, Turkey

Background/aim: The aim of this study was to determine the prevalence and associated factors of thrombocytopenia in human immunodeficiency virus (HIV)-infected patients. Materials and methods: A cross-sectional study was conducted in a tertiary care hospital in İzmir, Turkey. All HIV-infected patients admitted to the Department of Infectious Diseases and Clinical Microbiology between 2006 and 2011 were recruited. Patients with thrombocytopenia at any time point were defined as the case group and the remaining patients were defined as the control group. Results: The frequency of thrombocytopenia was 35.8%. Thrombocytopenia was more frequent in patients with acquired immune deficiency syndrome (AIDS) than in patients without AIDS (P < 0.05) and in antiretroviral-naive patients than in patients on combination antiretroviral therapy (cART) or those who had ever used cART in the past (P < 0.05). Additionally, rates of tuberculosis infection, prophylactic use of trimethoprim-sulfamethoxazole (TMP/SMX), and being anti-HCV seropositive at any time point were higher in patients with thrombocytopenia than in the control group (P < 0.05), and the case group had lower CD4+ T lymphocytes at first admission (P < 0.05). Conclusion: The main finding was the clear association between thrombocytopenia and advanced and uncontrolled HIV infection. Tuberculosis and HCV coinfections were also identified as associated factors for thrombocytopenia.

PDF

___

1. Spivak JL, Bender BS, Quin TC. Hematological abnormalities in the acquired immune deficiency syndrome. Am J Med 1984; 77: 224-228.
2. Coyle TE. Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Med Clin North Am 1997; 81: 449-470.
3. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ciesielski CA. Surveillance for thrombocytopenia in persons infected with HIV: results from the multistate Adult and Adolescent Spectrum of Disease Project. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 374-379.
4. Pearce CL, Mack WJ, Levine AM, Gravink J, Cohen MH, Machtinger EL, Anastos K, Silverberg MJ, Young MA, Minkoff H et al. Thrombocytopenia is a strong predictor of all-cause and AIDS-specific mortality in women with HIV: The Womens Interagency HIV Study. Blood 2004; 104: 569A-570A.
5. Johannessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, Aglen HE, Gundersen SG, Bruun JN. Predictors of mortality in HIVinfected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis 2008; 8: 52.
6. De Santis GC, Brunetta DM, Vilar FC, Brandão RA, de Albernaz Muniz RZ, de Lima GM, Amorelli-Chacel ME, Covas DT, Machado AA. Hematological abnormalities in HIV-infected patients. Int J Infect Dis 2011; 15: e808-811.
7. Sugiura K, Oyaizu N, Pahwa R. Effect of human immunodeficiency virus-1 envelope glycoprotein on in vitro hematopoiesis of umbilical cord blood. Blood 1992; 80: 1463-1469.
8. Calenda V, Chermann JC. The effects of HIV on hematopoiesis. Eur J Haematol 1992; 48: 181-186.
9. Scadden DT, Zon LI, Groopman GE. Pathophysiology and management of HIV-associated hematologic disorders. Blood 1989; 74: 1455-1463.
10. Zon LI, Groopman JE. Hematologic manifestations of the human immune deficiency virus (HIV). Semin Hematol 1988; 25: 208- 218.
11. Mitsuyasu RT. Clinical uses of hematopoietic growth hormones in HIV-related illnesses. AIDS Clin Rev 1993-1994; 189-212.
12. Moses A, Nelson J, Bagby GC Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood 1998; 91: 1479-1495.
13. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate Adult and Adolescent Spectrum of HIV Disease Surveillance Project. Blood 1998; 91: 301-308.
14. Fangman JJ, Scadden DT. Anemia in HIV-infected adults: epidemiology, pathogenesis, and clinical management. Curr Hematol Rep 2005; 4: 95-102.
15. Evatt BL. HIV Infection and thrombocytopenia. Curr Hematol Rep 2005; 4: 149-153.
16. Pechere M, Samii K, Hirschel B. HIV-related thrombocytopenia. N Engl J Med 1993; 328: 1785-1786.
17. Miguez-Burbano MJ, Jackson J Jr, Hadrigan S. Thrombocytopenia in HIV disease: clinical relevance, physiopathology and management. Curr Med Chem Cardiovasc Hematol Agents 2005; 3: 365-376.
18. Sloand EM, Klein HG, Banks SM, Vareldzis B, Merritt S, Pierce P. Epidemiology of thrombocytopenia in HIV infection. Eur J Haematol 1992; 48: 168-172.
19. Rossi G, Gorla R, Stellini R, Franceschini F, Bettinzioli M, Cadeo G, Sueri L, Cattaneo R, Marinone G. Prevalence, clinical, and laboratory features of thrombocytopenia among HIV-infected individuals. AIDS Res Hum Retroviruses 1990; 6: 261-269.
20. Peltier JY, Lambin P, Doinel C, Courouce AM, Rouger P, Lefrere JJ. Frequency and prognostic importance of thrombocytopenia in symptom-free HIV-infected individuals: a 5-year prospective study. AIDS 1991; 5: 381-384.
21. Mientjes GH, van Ameijden EJ, Mulder JW, van den Hoek JA, Coutinho RA, von dem Borne AE. Prevalence of thrombocytopenia in HIV-infected and non-HIV infected drug users and homosexual men. Br J Haematol 1992; 82: 615- 619.
22. Murphy MF, Metcalfe P, Waters AH, Carne CA, Weller IV, Linch DC, Smith A. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol 1987; 66: 337-340.
23. Kaslow RA, Phair JP, Friedman HB, Lyter D, Solomon RE, Dudley J, Polk BF, Blackwelder W. Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study. Ann Intern Med 1987; 107: 474-480.
24. Volberding PA, Baker KR, Levine AM. Human immunodeficiency virus hematology. Hematology Am Soc Hematol Educ Program 2003: 294-313.
25. Marks KM, Clarke RM, Bussel JB, Talal AH, Glesby MJ. Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 52: 595-599.
26. Firnhaber C, Smeaton L, Saukila N, Flanigan T, Gangakhedkar R, Kumwenda J, La Rosa A, Kumarasamy N, De Gruttola V, Hakim JG et al. Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas. Int J Infect Dis; 2010; 14: e1088-1092.
27. Güven GS, Çakır B, Tezcan S, Durusu Tanrıöver M, Dokuzoğuz B, Baykam N, Özkaya Sahin G, Ünal S. HIV/AIDS hastalarında yaşam süresi üzerine olan faktörlerin incelenmesi: iki merkezden 15 yıllık takip sonuçları. HIV/AIDS 2004; 7: 119- 126 (in Turkish).
28. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19.
29. Frontiera M, Myers AM. Peripheral blood and bone marrow abnormalities in the acquired immunodeficiency syndrome. West J Med 1987; 147: 157-160.
30. Ambler KL, Vickars LM, Leger CS, Foltz LM, Montaner JS, Harris M, Dias Lima V, Leitch HA. Clinical features, treatment, and outcome of HIV-associated immune thrombocytopenia in the HAART era. Adv Hematol 2012; 2012: 910954.
31. Choi SY, Kim I, Kim NJ, Lee SA, Choi YA, Bae JY, Kwon JH, Choe PG, Park WB, Yoon SS et al. Hematological manifestations of human immunodeficiency virus infection and the effect of highly active anti-retroviral therapy on cytopenia. Korean J Hematol 2011; 46: 253-257.
32. Kouri YH, Borkowsky W, Nardi M, Karpatkin S, Basch RS. Human megakaryocytes have a CD4 molecule capable of binding human immunodeficiency virus-1. Blood 1993; 81: 2664-2670.
33. Alaei K, Alaei A, Mansoori D. Thrombocytopenia in HIVinfected patients, Islamic Republic of Iran. East Mediterr Health J 2002; 8: 758-764.
34. Eyster ME, Rabkin CS, Hilgartner MW, Aledort LM, Ragni MV, Sprandio J, White GC, Eichinger S, de Moerloose P, Andes WA et al. Human immunodeficiency virus-related conditions in children and adults with hemophilia: rates, relationship to CD4 counts and predictive value. Blood 1993; 81: 828-834.
35. Carbonara S, Fiorentino G, Serio G, Maggi P, Ingravallo G, Monno L, Bruno F, Coppola S, Pastore G, Angarano G. Response of severe HIV-associated thrombocytopenia to highly active antiretroviral therapy including protease inhibitors. J Infect 2001; 42: 251-256.
36. Bouldouyre MA, Charreau I, Marchou B, Tangre P, Katlama C, Morlat P, Meiffredy V, Vittecoq D, Bierling P, Aboulker JP et al. Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial. J Acquir Immune Defic Syndr 2009; 52: 531-537.
37. Servais J, Nkoghe D, Schmit JC, Arendt V, Robert I, Staub T, Moutschen M, Schneider F, Hemmer R. HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 28: 221225.
38. Rieg G, Yeaman M, Lail AE, Donfield SM, Gomperts ED, Daar ES; Hemophilia Growth and Development Study (HGDS). Platelet count is associated with plasma HIV type 1 RNA and disease progression. AIDS Res Hum Retroviruses 2007; 23: 1257-1261.
39. Arranz Caso JA, Sanchez Mingo C, Garcia Tena J. Effect of highly active antiretroviral therapy on thrombocytopenia in patients with HIV infection. N Engl J Med 1999; 341: 1239- 1240.
40. Ananworanich J, Phanuphak N, Nuesch R, Apateerapong W, Rojnuckarin P, Ubolyam S, Phanuphak P, Ruxrungtham K. Recurring thrombocytopenia associated with structured treatment interruption in patients with human immunodeficiency virus infection. Clin Infect Dis 2003; 37: 723-725.
41. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, Hirschel B, Vernazza P, Francioli P, Greub G et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358: 1322-1327.
42. McShane H. Co-infection with HIV and TB: double trouble. Int J STD AIDS 2005; 16: 95-100.
43. Rothfield TG, Bierer WF, Garfield JW. Isoniazid induction of antinuclear antibodies. Ann Intern Med 1978; 88: 650-652.
44. Chan ED, Chatterjee D, Iseman MD, Heifets LB. Pyrazinamide, ethambutol, ethionamide and aminoglycosides. In: Rom WN, Garay SM, editors. Tuberculosis. 2nd ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2004. pp. 773-789.
45. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Disease Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
46. World Health Organization (WHO). Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. WHO/HTM/TB/2006.361. Geneva, Switzerland: WHO; 2006.
47. Ciernik IF, Cone RW, Fehr J, Weber R. Impaired liver function and retroviral activity are risk factors contributing to HIVassociated thrombocytopenia. Swiss HIV Cohort Study. AIDS 1999; 13: 1913-1920.
48. Galli M, Musicco M, Gervasoni C, Ridolfo AL, Niero F, Rusconi S, Riva A, Voltolin L, Lupo A, Lovicu GF et al. No evidence of a higher risk of progression to AIDS in patients with HIV1-related severe thrombocytopenia. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12: 268-275.
49. Holzman RS, Walsh CM, Karpatkin S. Risk for the acquired immunodeficiency syndrome among thrombocytopenic and nonthrombocytopenic homosexual men seropositive for the human immunodeficiency virus. Ann Intern Med 1987; 106: 383-386.
50. Karpatkin S. HIV-1-related thrombocytopenia. Baillieres Clin Haematol 1990; 3: 115-138.